Clinical Trial Update: A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years [Phase 3]

View source ↗

Summary

This Phase 3 clinical trial update describes a study of oral atogepant in adolescents aged 12 to 17 with chronic migraine to assess adverse events and changes i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Qulipta (atogepant)

Snippet

Sponsor: AbbVie | Conditions: Chronic Migraine | Phase 3 | Status: RECRUITING